These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16990762)

  • 1. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 3. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
    [No Abstract]   [Full Text] [Related]  

  • 7. Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Pich A; Godio L; Riera L; Cavaliere C; Kerim S; Bonello L; Francia di Celle P
    Ann Hematol; 2016 Feb; 95(3):525-7. PubMed ID: 26750119
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 9. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 10. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
    Med Lett Drugs Ther; 2006 Apr; 48(1232):31-2. PubMed ID: 16625140
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
    Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
    Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
    [No Abstract]   [Full Text] [Related]  

  • 16. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
    Lancet JE; List AF; Moscinski LC
    Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
    [No Abstract]   [Full Text] [Related]  

  • 18. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
    Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
    Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
    Cerchione C; Catalano L; Cerciello G; Avilia S; Picardi M; Risitano AM; Pisano I; Alfinito F; Pane F
    Ann Hematol; 2015 Mar; 94(3):531-4. PubMed ID: 25135452
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
    Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
    Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.